Summary & Overview
HCPCS Level II J9010: Alemtuzumab Injection, 10 mg
HCPCS Level II code J9010 denotes a 10 mg injection of alemtuzumab, an oncology-focused monoclonal antibody administered via infusion. Nationally, this code is used in outpatient infusion centers and hospital outpatient departments to capture drug acquisition and administration for patients receiving targeted hematology-oncology therapy. Precise coding for high-cost biologic agents like alemtuzumab is important for claims processing, clinical documentation, and tracking utilization of specialty therapies.
Key payers discussed include Blue Cross Blue Shield and Cigna Health. The publication covers payer coverage considerations, coding and billing context for infusion-based monoclonal antibodies, and how J9010 fits within related drug code groupings. Readers will find an overview of typical clinical indications tying the code to oncology and hematology practice, common service locations, and links to adjacent codes used for comparable monoclonal antibody injections.
Where input details are incomplete, the publication notes data limitations rather than inferring missing elements. The content is intended for billing managers, revenue cycle professionals, and clinicians involved in oncology drug administration who need a concise reference to the clinical and billing context of HCPCS Level II code J9010.
Billing Code Overview
HCPCS Level II code J9010 represents an injection of alemtuzumab, 10 mg, a monoclonal antibody therapy used in oncology and hematology care. The code applies to administration of the specified drug preparation and is associated with infusion-based treatment.
Service type: Oncology / Hematology (monoclonal antibody therapy)
Typical site of service: Infusion center or hospital outpatient setting (for example, POS 22).
Data not available in the input for additional billing line metadata.
Clinical & Coding Specifications
A patient with a hematologic or oncologic malignancy presents to an infusion center or hospital outpatient department for monoclonal antibody therapy. The ordering oncologist prescribes alemtuzumab dosed in 10 mg increments to treat or manage disease activity. On arrival, the patient undergoes intake triage (vital signs, allergy review, premedication assessment), venous access placement, and administration of alemtuzumab via intravenous infusion by an oncology-certified RN in a monitored infusion chair or curtained bay. Continuous monitoring for infusion reactions and hematologic or infectious complications occurs during and after the infusion per institutional protocols. Drug handling includes pharmacy preparation under aseptic technique, documentation of lot number and expiration, and recording of units administered and any portion discarded. Billing uses HCPCS Level II code J9010 to report alemtuzumab, 10 mg, with applicable modifiers for discarded drug (JW) or if a distinct procedural service is provided (59). Typical sites of service include infusion center or hospital outpatient (e.g., POS 22). Associated provider specialties include hematology/oncology and medical oncology clinicians responsible for prescribing and supervising therapy.
Modifiers:
-
JW: Drug amount discarded/not administered to any patient — Append when any portion of the dispensed alemtuzumab is discarded and not administered; document discarded amount and rationale per payor policy. -
59: Distinct Procedural Service — Append when the infusion or related service is distinct and separate from other services provided on the same day; support with documentation that the service is separate and unrelated to other procedures.
Provider Taxonomies: